P-21
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
P-21 is used as a structural cognition experiment: the intended effect is better hippocampal neurogenesis, BDNF signaling, memory consolidation, and learning retention over a multi-week course.
Low acute toxicity signal in community use, but the safety record is still preclinical and sparse: no human trials, no human pharmacokinetics, and no long-term neurological follow-up.
P-21 is used as a structural cognition experiment: the intended effect is better hippocampal neurogenesis, BDNF signaling, memory consolidation, and learning retention over a multi-week course. It is not meant to feel like a stimulant or same-day focus drug; the article evidence frames useful response as something that should emerge over 1-2 weeks with active learning and sleep support.
Common reported issues are vivid dreams, transient headache, mild emotional sensitivity, and first-week fatigue. The article does not show cardiovascular, hepatic, renal, endocrine, dependency, or withdrawal signals, but long-term human safety is unknown and broader cell-proliferation concerns remain theoretical rather than resolved.
P-21 is useful only if the buyer wants a narrow, mechanism-specific neurogenesis experiment. It targets the CNTFRalpha/JAK-STAT/BDNF lane rather than acute neurotransmitter modulation, making it more interesting than standard nootropics for structural memory work but much weaker than Cerebrolysin on clinical validation.
Mixed but not empty: community responders report better memory, learning, clarity, and sleep quality over 2-4 weeks, while a meaningful non-responder cohort reports little from full courses, especially with intranasal spray. SubQ is the favored route when the goal is sustained structural effect.
Do not treat P-21 as a simple add-on if cortisol is chronically high, sleep is poor, or the protocol is mostly passive. Those conditions work against the neurogenesis mechanism and make the course hard to interpret.
Intro
P-21 (also designated P021 or Peptide 6) is a synthetically engineered hexapeptide derived from ciliary neurotrophic factor (CNTF), specifically the residue 147-150 active motif DGGL of the parent neurotrophin.
The full structure is Ac-DGGLAG-NH2 — N-terminally acetylated and C-terminally amidated — with a critical adamantane moiety attached at glycine position 5. That adamantane modification is what separates P-21 from a generic CNTF fragment: it provides the lipophilicity needed to cross the blood-brain barrier, protects against exopeptidase degradation, and extends plasma half-life. Molecular weight is approximately 578.3 g/mol, below the BBB exclusion threshold.
P-21 originated through epitope mapping of Cerebrolysin, a complex multi-peptide preparation from purified porcine brain proteins that has been used clinically in Europe and Asia for decades to treat Alzheimer's disease, stroke, and traumatic brain injury. Cerebrolysin's active fractions include CNTF-like neurotrophic peptides; P-21 is the isolated synthetic version of one of those active motifs, engineered to retain neurotrophin signaling while eliminating the adverse effects of full-length CNTF administration — particularly the weight loss and immunogenicity that made direct CNTF administration clinically impractical.
The evidence base for P-21 is narrow by design. Approximately five peer-reviewed studies from a single research group — Iqbal and colleagues at the New York State Institute for Basic Research — conducted in rodent models form the entire published preclinical record. No human clinical trials have been registered or completed. The rodent signal is internally consistent across those studies, but has not been independently replicated by other laboratories. That provenance — a strong rodent signal from one lab — is the starting point, not a finished efficacy profile.
Community interest in P-21 stems from its proposed mechanism: rather than modulating neurotransmitter signaling in existing circuits (the mechanism of most nootropics, from racetams to Semax), P-21 targets the generation of new neurons in the hippocampal dentate gyrus, the brain region central to memory formation and spatial navigation. This positions it as a structural rebuilding tool with a fundamentally different timescale from acute cognitive enhancers. Effects, when they occur, emerge over 1-2 weeks — the time required for new neurons to form, migrate, and begin integrating into existing hippocampal circuits.
P-21 is frequently confused with the CDKN1A gene product (the p21Cip1/WAF1 cell cycle inhibitor, an entirely different molecule used in cancer biology) and with Adamantyl-Semax, which uses the same adamantane modification strategy but acts via a completely different receptor target. For the nootropic/peptide community, P-21 refers exclusively to the CNTF-derived compound described here.
Observed Effects
The reported cognitive effects of P-21 are structural in character — they build across a course rather than manifesting acutely.
The most consistent community observations are: improved memory retention and recall consolidation, enhanced ability to acquire and retain new information (learning), increased mental clarity and focus that develops over 1-2 weeks of continuous use, and in some users a notable improvement in sleep quality, particularly deep or restorative sleep.
First-person reports from early nootropic communities describe a range of effects. In stacked protocols with other wakefulness agents, users report dramatic improvements in focus, social confidence, memory retention, alertness, and fatigue relief — though attribution to P-21 specifically is impossible given co-administration. In solo intranasal use, other users report occasional clarity, calm, and focus but uncertainty about lasting cognitive change.
This responder variability is real. Some users report dramatic, meaningful improvements in cognitive function across memory, focus, and mood. Others complete a full course and report minimal discernible effect. The community hypothesis is that individual differences in baseline hippocampal neurogenesis capacity, cortisol levels (which suppress neurogenesis), lifestyle co-factors, and route of administration all influence response. SubQ administration is consistently considered more likely to produce structural effects than intranasal spray.
In the preclinical literature, rodent studies from a narrow lab lineage document improved spatial learning and memory in aged animal models, increased hippocampal BDNF expression, enhanced dendritic spine density in hippocampal CA1 pyramidal neurons, and reduced tau hyperphosphorylation in Alzheimer's disease mouse models — the last of these suggesting potential disease-modifying properties beyond simple cognitive enhancement.
P-21 is not a mood compound in the primary sense, though some users report secondary improvements in mood, social ease, and anxiety reduction. These may reflect downstream effects of improved hippocampal function (the hippocampus is heavily implicated in mood regulation through its connections to the limbic system) rather than direct serotonergic or noradrenergic action.
Field Reports
First-person experience data for P-21 is sparse relative to the community interest level. The most detailed reports come from early nootropic-forum discussions rather than controlled human studies.
The most enthusiastic first-person accounts describe users running P-21 alongside other wakefulness or neuroactive compounds, with dramatic reports of improved focus, memory retention, social confidence, and fatigue relief. The P-21 contribution cannot be isolated in those cases because companion compounds can have potent immediate effects on wakefulness, social drive, and motivation.
More cautious solo reports describe the experience as interesting but far less dramatic than the hype, with occasional clarity, calm, focus, and sleep-quality changes. Some users report that P-21 can feel either stimulating or sedating on different occasions, possibly reflecting variation in whether the neurogenic response feels more activating or restorative on a given day.
Community ambivalence is real. Many users who tried intranasal formats reported insufficient response and wondered whether injectable routes would deliver better sustained effects, but the discussion base is thin relative to the size of the question.
The overall community experience profile: a meaningful subset of users reports real cognitive improvements in memory, focus, and learning speed over a 2-4 week course; a similar-sized cohort reports minimal discernible effect. Non-responders disproportionately used the intranasal spray route. The dream intensity effect is the most consistently reported secondary finding across all user accounts.
Community Consensus
P-21 occupies a specific and consistent niche in the cognitive enhancement community: advanced users who have exhausted the standard nootropic toolkit — racetams, adaptogens, peptide stacks like Semax and Selank — and are seeking a compound that targets hippocampal neurogenesis directly rather than modulating existing neural circuits. The community skews toward older biohacker circles, longevity researchers, and users managing cognitive decline or neurodegenerative risk factors.
The compound's defining community feature is the structural timescale debate. P-21 is not expected to produce day-1 effects. Community consensus holds that the compound requires 1-2 weeks of daily dosing before subjective changes appear, if they appear at all. This patience requirement filters for a specific user type — those willing to run a structured course with careful tracking, rather than those seeking immediate nootropic feedback.
P-21 vs. Cerebrolysin is the dominant community comparison. Both compounds trace to CNTF neurotrophic signaling. The community verdict is not a clear winner — Cerebrolysin has superior clinical evidence and broader neurotrophic coverage; P-21 is single-compound and lower-friction but much less clinically validated.
Responder variability is a persistent community topic. Some users report significant improvements; others complete a full course with nothing to show for it. The community consensus on improving response is to prefer route consistency for structural goals, maintain active cognitive engagement during the cycle, optimize sleep quality, and rule out high cortisol as a suppressor of neurogenesis.
P-21's popularity peaked when the core preclinical papers were fresh. Interest has been maintained but not grown significantly as the absence of human data has prevented it from crossing into mainstream peptide market popularity.
Risks & Monitoring
P-21 has a limited but consistent adverse effect profile across community sources. No cardiovascular, hepatic, renal, or endocrine adverse effects have been reported.
No psychostimulant effects, dependency, or withdrawal are reported. The compound does not produce the acute side effects associated with peptides that act on central neurotransmitter release.
Consistently reported across multiple community sources: vivid or unusual dreams, especially in the first 1-2 weeks of a cycle. This is considered a positive signal by some users — interpreted as evidence that hippocampal neurogenesis is occurring and integrating into the REM consolidation process — but it is disruptive for others. Mild emotional sensitivity or 'emotional rawness' is also reported, particularly early in a course.
Transient headache in the first few days of use is noted by some sources, especially with intranasal administration. The headache typically resolves without intervention. A building fatigue during the first week — described as a body-building-something feeling that resolves with sleep — is reported in community accounts. This fatigue is interpreted as a metabolic cost of active neurogenesis.
Hair thinning is mentioned anecdotally at heavy doses. This is not confirmed across multiple independent sources and should be treated as unsubstantiated anecdote rather than an established risk. No mechanistic explanation for a hair thinning effect is proposed in the source material.
Long-term human safety is unknown. Preclinical summaries reference a favorable safety profile up to 18 months duration — this is rodent data, not human safety monitoring. Given that P-21 upregulates BDNF and promotes cell proliferation in the hippocampus, theoretical concerns about effects on broader cell proliferation pathways have been raised in the community, though no actual oncological signals have been reported at community doses.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
P-21's structural timescale means effects develop over weeks, and the responder/non-responder split is central to the article. A baseline subjective rating of memory, focus, learning retention, sleep quality, and dream intensity is the minimum way to know whether the course did anything after 2-4 weeks. Standardized tools (digit span, word recall, reaction time apps) are more useful than general impression.
Elevated cortisol suppresses hippocampal neurogenesis, the primary mechanism of P-21. Baseline cortisol identifies users who may have blunted neurogenic response from chronic stress — providing context if the compound underdelivers.
BDNF upregulation is P-21's primary downstream mechanism. Serum BDNF correlates imperfectly with brain BDNF but provides a proxy signal for whether the compound is engaging its intended pathway. Not commonly ordered but available through specialty labs.
Standard safety baseline for any peptide protocol. P-21 has no known hepatic or hematological signals, but baseline health status informs interpretation of any unexpected changes.
Avoid With
Do not combine P-21 with the following. Sorted highest-severity first.
Why:Glucocorticoids (cortisol, prednisone) suppress hippocampal neurogenesis — the primary mechanism P-21 is trying to engage. Chronic psychological stress with sustained cortisol elevation would be expected to blunt P-21 response. Not a drug interaction per se, but a physiological antagonism of mechanism.
What to do:Users with chronically elevated cortisol from psychological stress or medical glucocorticoid use should address that factor before expecting P-21 to produce neurogenic effects.
Why:High-dose stimulants (amphetamines, high-dose caffeine, modafinil at ceiling doses) may interfere with BDNF expression and hippocampal plasticity through adrenergic mechanisms. Low-moderate caffeine use is unlikely to be problematic.
What to do:This is a theoretical concern based on mechanism, not a documented community drug interaction.
Why:Chronic NSAID use has been associated with reduced neurogenesis in some rodent models, potentially through COX-2 inhibition and secondary effects on BDNF. No human or clinical data specific to P-21 + NSAID interaction.
What to do:Occasional NSAID use is unlikely to be meaningful. Chronic daily use during a P-21 cycle is a theoretical concern worth noting.
Protocols By Goal
Memory consolidation and learning enhancement: SubQ 100-300 mcg daily for 30 days. Stack with daily cognitive challenges, new skill acquisition, or structured learning tasks during the cycle — use-dependent plasticity means new hippocampal neurons integrate more effectively when the learning environment is active. Quality sleep (7-9 hours) is critical for consolidation. Repeat 2-3× per year.
Neuroprotection and cognitive maintenance (aging): SubQ 500 mcg to 1 mg daily for 30 days, 2× per year. Add dietary omega-3 and choline support. Consider Semax as an immediate-acting complement during the cycle to bridge the structural lag period.
Neurodegeneration research / Alzheimer's model context: The preclinical evidence specifically targeted aged rodent models and Alzheimer's disease models. Community users exploring this application typically run longer cycles (8-12 weeks SubQ) at 1-3 mg/day and may stack with Dihexa (HGF-mediated synaptogenesis via complementary pathway). No human data exists for this application.
Acute cognitive focus (not a primary indication): P-21 is not designed for day-to-day cognitive performance improvement. Users expecting Semax-like acute clarity from day 1 will be disappointed. Those seeking an acute complement during a P-21 cycle typically add Semax (for immediate BDNF/AMPA effect) or Selank (for anxiolytic calm).
Dosing Details
All P-21 human dosing is extrapolated from rodent intraperitoneal (IP) protocols — no human pharmacokinetic data exists for any route.
The community has empirically converged on doses well below naive bodyweight-scaling from rodent IP data, reflecting the acknowledged higher bioavailability of IP versus SubQ or intranasal administration in rodents.
Subcutaneous use is the most commonly recommended route for sustained structural effects in community discussion, with users generally describing low-mcg to low-mg daily exposure over multi-week courses. This is reported practice, not a validated human protocol.
Intranasal use is preferred by some for direct CNS delivery via olfactory pathway, but community experience suggests acute effects may be more noticeable while sustained structural effects are less reliable. Route preparation and preservative choice are handling-risk topics, not settled efficacy guidance.
Storage and post-mixing handling follow general peptide-practice assumptions rather than P-21-specific human pharmacokinetic validation.
Stacks & Alternatives
P-21 provides CNTFRa/JAK-STAT/BDNF-driven hippocampal neurogenesis; Semax provides immediate BDNF and AMPA receptor enhancement bridging the structural lag; Dihexa provides HGF/c-Met synaptogenesis via a completely distinct pathway. Mechanistic complementarity — three different molecular levers on hippocampal plasticity. Community discussions often call this the 'neurogenesis stack.'
Semax for cognitive enhancement during the P-21 structural lag; Selank for anxiolytic complement that some users find improves the mild emotional sensitivity reported early in P-21 cycles. Both are nasal spray peptides that can be dosed separately from P-21 SubQ injections. Community pattern documented across multiple peptide protocol sites.
P-21 and Cerebrolysin both trace to CNTF neurotrophic signaling but via different delivery mechanisms — P-21 as a single synthetic peptide, Cerebrolysin as a complex multi-peptide preparation with broader neurotrophic coverage (NGF, BDNF, NT-3, NT-4 fractions). Theoretically complementary but expensive and practically difficult given Cerebrolysin's IM/IV administration requirements. Used by advanced community users seeking maximal neurotrophin support.
Alternatives
Stack Cost
Low tax: P-21 does not consume endocrine, liver, lipid, blood-pressure, or PCT capacity, but it still consumes injection discipline, sourcing judgment, sleep/cortisol context, and a tracking plan because response is subtle and slow.
Daily SubQ injection is the route most associated with structural protocols in the article; intranasal dosing lowers injection burden but is less reliable in community reports.
No safety-critical bloodwork is established, but a baseline cognitive/sleep log is required for interpretation. Optional cortisol and BDNF testing are context tools rather than hard safety gates.
The efficacy case is rodent-heavy, single-lab, and not supported by human pharmacokinetic data. That uncertainty increases decision tax even when the physiological side-effect burden looks light.
The article repeatedly ties response to sleep quality, active learning, and cortisol control. Poor sleep or chronic high-stress states can turn a low-toxicity protocol into an uninterpretable one.
- ·No hormonal suppression — compatible with TRT, GH axis compounds, and SERM/AI protocols without interaction
- ·No hepatic metabolic load — safe to combine with oral androgens or other hepatically active compounds without adding liver stress
- ·No CNS neurotransmitter depletion — stacks cleanly with Semax, Selank, and other neuropeptides without obvious receptor competition
- ·Counts as a slow neuroplasticity lane, not an acute focus lane; do not use it to replace sleep, learning structure, or a faster-acting nootropic when the need is same-day performance.
- ·Escalate the tax if the user is also running experimental neurogenesis or synaptogenesis compounds such as Dihexa, because long-term safety and attribution become much harder to interpret.
- ·Sterile SubQ injection supplies and refrigerated post-mixing storage if using the preferred structural route.
- ·A 2-4 week cognitive and sleep tracking baseline with at least one repeatable memory or attention measure.
- ·A sleep and stress plan before the course, because poor sleep and high cortisol directly work against the intended neurogenesis mechanism.
- ·Product-quality review and compound-name disambiguation, since P-21 searches are easily contaminated by unrelated CDKN1A/p21 biology.
The acute adverse-effect burden is light, but the article's decision burden is not: P-21 has no human PK, no human trials, route uncertainty, response ambiguity, and a structural effect that requires patient tracking rather than immediate feedback.
- ·The user expects acute stimulant-like focus from day 1
- ·The user cannot distinguish P-21 from CDKN1A/p21 search contamination or unrelated adamantane peptides
- ·The user has unmanaged chronic stress, poor sleep, or exogenous glucocorticoid exposure and wants to judge efficacy anyway
- ·The user plans to stack several experimental cognition compounds without attribution rules
The article describes no withdrawal, no endocrine suppression, and no taper requirement. The main off-ramp problem is interpretation: a non-response may reflect route, source quality, poor sleep, high cortisol, or the compound simply not translating to that user.
- ·Loss of any sleep-quality or dream-intensity changes that occurred during the course
- ·Unclear attribution if P-21 was stacked with Orexin-A, Semax, Dihexa, or multiple nootropics
- ·Temptation to extend or raise dose because the structural effect is slow and subtle
Frame the course as a 2-4 week structural experiment and collect baseline measures before dosing.
Use quality-verified lyophilized material, prefer SubQ for structural goals, and avoid interpreting a failed nasal spray as proof the mechanism is false.
Fix sleep and stress substrate first; run P-21 alongside active learning rather than passive routines.
Keep the first course as clean as possible or stagger additions so acute wakefulness, anxiolysis, and neurogenesis signals are not collapsed into one story.
womenConsiderations marks pregnancy contraindicated because fetal, lactation, and fertility safety data are absent.
The article identifies cortisol as a primary suppressor of hippocampal neurogenesis, directly opposing P-21's intended mechanism.
P-21's effect is slow, subtle, and variable; without tracking, response and non-response are both hard to interpret.
Overstacking makes attribution impossible and compounds long-term uncertainty around neurogenesis and synaptogenesis pathways.
Practical Setup
P-21 is a research compound with no established human dosing, pharmacokinetic data, or safety profile.
All dosing protocols extrapolate from rodent intraperitoneal studies with IP bioavailability substantially higher than SubQ or intranasal routes. The correct dose for any individual is unknown.
Route choice matters: SubQ is often treated as the preferred route for structural neurogenic goals. Intranasal is preferred by some for acute CNS delivery via olfactory pathway, but community experience suggests lower reliability for sustained structural effects. Route preparation and preservative selection are handling-risk topics, not settled evidence.
Lifestyle co-factors are not optional context — they are mechanistically load-bearing for P-21's mechanism to produce results. New hippocampal neurons integrate most effectively when the learning environment is demanding and rich. A P-21 cycle run alongside passive activities is expected to produce weaker effects than one run during active learning, skill acquisition, or intellectually demanding periods. Sleep quantity and quality drive memory consolidation that newly generated neurons participate in.
Cortisol is the primary suppressor of hippocampal neurogenesis. Users under chronic psychological stress, or taking exogenous glucocorticoids, may have blunted P-21 response. Addressing stress management, sleep quality, and dietary choline/omega-3 intake before a cycle improves the substrate for neurogenesis.
The compound's 'structural timescale' means that judging response before 2 weeks is premature. Day-1 effects (if any) are not mechanistically expected and may reflect other neurological processes or placebo effects. A minimum 2-4 week continuous protocol before assessing response is the community consensus minimum.
Quality considerations: P-21 is a niche research peptide, not a clinically regulated medicine. Identity, purity, storage, and route format can all confound response or adverse effects.
Disambiguation for search: P-21 the nootropic peptide is entirely different from p21Cip1/WAF1 (CDKN1A, a cell cycle inhibitor central to cancer biology) and from P21 as a designation used for unrelated compounds in other clinical contexts. Search contamination by the CDKN1A literature is substantial when searching for 'p21 clinical effects' — clinical search results are almost entirely wrong compounds.
Mechanism Deep Dive
P-21's mechanism begins at the CNTFRalpha/gp130/LIFRbeta receptor complex — the same trimeric receptor system activated by full-length ciliary neurotrophic factor (CNTF).
The adamantane-modified DGGL motif engages CNTFRalpha specifically, triggering JAK (Janus kinase) phosphorylation and STAT (Signal Transducer and Activator of Transcription) signaling. JAK/STAT activation is the canonical neurotrophin intracellular signaling pathway downstream of CNTFRalpha engagement.
The primary downstream consequence of JAK/STAT activation in hippocampal neurons is transcriptional upregulation of BDNF (Brain-Derived Neurotrophic Factor) — both mRNA expression and protein production increase in the hippocampus. BDNF is the principal mediator of adult hippocampal neurogenesis: it promotes the survival, proliferation, and differentiation of neural progenitor cells in the dentate gyrus subgranular zone, the primary site of adult neurogenesis in the mammalian hippocampus.
Downstream of BDNF elevation: enhanced long-term potentiation (LTP) — the synaptic strengthening mechanism underlying memory consolidation — through BDNF's role in AMPA receptor trafficking and synaptic protein synthesis. Dendritic arborization (increased branching and spine density) producing more synaptic connection sites, particularly in CA1 pyramidal neurons. And in Alzheimer's disease rodent models, reduction of tau hyperphosphorylation — one of the two major pathological hallmarks of AD — suggesting a potential disease-modifying property beyond simple neurogenesis.
The adamantane moiety that enables BBB penetration also protects the peptide from exopeptidase cleavage in circulation, extending its effective half-life. The peptide is below the molecular weight threshold (578.3 g/mol) that would exclude it from passive transcytosis across the blood-brain barrier, and its engineered lipophilicity facilitates membrane interaction at the BBB interface.
P-21 was engineered to circumvent the clinical liabilities of direct CNTF administration: full-length CNTF causes severe weight loss, inflammatory cytokine release, and immunogenicity in humans — effects that terminated several CNTF clinical trials in the 1990s. By delivering only the active CNTFRalpha-binding motif in a modified, proteolysis-resistant form, P-21 retains the neurotrophin signaling axis without triggering the systemic cytokine cascade of the full protein.
The structural timescale of P-21's effects is a direct consequence of this mechanism: neurogenesis (the birth, migration, and circuit integration of new neurons) requires weeks, not hours. Dendritic spine formation and synaptic strengthening via BDNF also occur on days-to-weeks timescales. This is fundamentally different from compounds that modulate neurotransmitter release (Semax, racetams) or block ion channels (PE-22-28's TREK-1 mechanism), which produce effects within hours.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
P-21 administered at 1mg/kg daily for 14 days in rodents increased hippocampal BDNF expression by approximately 47% compared to baseline
Secondary-source figure that could not be independently verified against the original paper; treat as indicative rather than confirmed.
P-21 improved dendritic spine density in hippocampal CA1 pyramidal neurons after 14-day IP protocol at 1mg/kg
Attributed to a primary literature citation by a secondary source but not independently verified. This specific citation requires primary source confirmation before clinical extrapolation.
P-21 reduces tau hyperphosphorylation in Alzheimer's disease mouse models
Attributed to a narrow preclinical research lineage by secondary summaries. One of the downstream effects cited as evidence for disease-modifying potential.
P-21 improved spatial learning and memory in aged animal models
Attributed to the same preclinical research lineage. Multiple community sources cite this finding. Represents the primary behavioral outcome of the preclinical evidence base.
Vivid dreams and mild emotional sensitivity are the most consistently reported adverse effects during P-21 use
Aggregated across early nootropic-forum reports, community summaries, and peptide information sites. Consistent across independent sources.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.